Money is flowing into cannabis equities at a pace the sector hasn't seen in years, and the numbers make the point plainly. The AdvisorShares Pure US Cannabis ETF (MSOS) posted a 103.7% one-year net asset value return as of May 31, dwarfing the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8% return over the same stretch. Over the past three months alone, MSOS climbed 28% while the broader marijuana benchmark actually slipped about 1%, a divergence that tells you this rally is concentrated, not sector-wide.

What's driving it is a stack of regulatory catalysts landing almost on top of each other. Trulieve Cannabis, MSOS' largest holding at roughly 30% of assets, began trading on the NYSE under the ticker TRLV, a move CEO Kim Rivers called a historic milestone. The company separated its medical cannabis operations from its adult-use business specifically to clear the bar for a senior exchange listing - a structural workaround that other multi-state operators are watching closely as they weigh their own uplisting paths. For operators managing that transition, the back-office lift is real: audited financials, board governance standards and investor-relations infrastructure that most cannabis companies never had to build under OTC listing rules. None of that happens without clean data underneath it, which is why point-of-sale and inventory platforms built for compliance - the kind of best cannabis software ohio operators rely on for seed-to-sale accuracy - matter more than ever as companies prepare their books for institutional scrutiny. best cannabis software ohio

The DEA Hearing Behind the Rally

The real test comes June 29, when a DEA administrative hearing opens to examine whether broader marijuana products, including adult-use cannabis, should move to Schedule III. The proceeding is expected to run through no later than July 15. This follows Acting Attorney General Todd Blanche's April action placing state-licensed medical marijuana products into Schedule III, a shift that eliminated tax penalties tied to Section 280E for licensed medical operators and let them start deducting ordinary expenses like payroll, rent and interest. Trump's formal nomination of Blanche to serve as attorney general permanently only added to the bullish read on where this process is headed. Fair enough - but a hearing isn't a ruling, and operators building financial projections around adult-use rescheduling are still, technically, betting on an outcome.

What Rescheduling Actually Changes for Operators

AdvisorShares argues the shift could strengthen earnings, free cash flow and balance sheets across the industry while opening doors to banking services and institutional capital that have been largely closed since legalization began. Roth Capital called the rescheduling order extremely favorable for taxation, capital access and future uplistings. That's already showing up in deal activity: Cresco Labs secured a $50 million revolving credit facility from Needham Bank this week, which CEO Charlie Bachtell described as a non-dilutive tool for acquisitions and a step toward eventual uplisting. Tilray, though not part of MSOS, has signaled it may deploy proceeds from its at-the-market program toward acquisitions as reform gains traction. In practice, though, none of this changes the day-to-day compliance burden - seed-to-sale tracking, lab testing, COA verification and cashless payment workarounds remain fixed costs of doing business in a federally illegal-but-tolerated market.

Where the Upside Looks Concentrated

Trulieve gets the headlines, but it's not where analysts see the steepest upside. Verano carries a 195% implied upside per price targets, followed by Jushi Holdings at 183% and Cresco Labs near 99%. Among the larger holdings, Green Thumb Industries shows a 70% upside - well ahead of both Trulieve and Curaleaf, the world's largest cannabis company by revenue. Retail sentiment on platforms like Stocktwits runs extremely bullish on MSOS, Trulieve and Green Thumb, with high message volume across the board.

• MSOS managed $1.13 billion in assets as of June 5
• Trulieve's NYSE listing followed a legal separation of its medical and adult-use businesses
• Schedule III reclassification removes 280E tax penalties for medical cannabis operators
• The DEA hearing on broader rescheduling runs June 29 through no later than July 15

For dispensary operators and multi-state companies watching from outside the public markets, the lesson isn't about stock prices - it's about preparedness. Whether or not adult-use rescheduling clears the DEA hearing, the operators positioned to benefit will be the ones with clean compliance records, defensible financials and inventory systems that can withstand institutional due diligence. That's a business discipline worth building regardless of how the hearing turns out.